Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Highly refractory acute myeloid leukemia.

Wolfgang Füreder1, Martin Filipits, Wolfgang R Sperr

  • 1Division of Hematology and Hemostaseology, The University of Vienna, Austria. wofuer@netway.at

Wiener Klinische Wochenschrift
|October 9, 2004
PubMed
Summary

This study identifies a highly refractory subgroup of acute myeloid leukemia (AML) patients. These patients show high expression of drug transporters and complex genetic changes, indicating poor treatment response.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial.

NPJ breast cancer·2026
Same author

Comparative analysis of four PFAS regarding their toxicity to zebrafish development.

Ecotoxicology and environmental safety·2026
Same author

ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34.

Breast (Edinburgh, Scotland)·2025
Same author

Reply to: Germline and Somatic <i>BRCA1/2</i> Mutations in Breast Cancer Treatment Strategies.

JCO precision oncology·2025
Same author

Federated Deep Learning Enables Cancer Subtyping by Proteomics.

Cancer discovery·2025
Same author

The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma.

Cancers·2025

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute myeloid leukemia (AML) poses treatment challenges, particularly in patients resistant to induction chemotherapy.
  • Identifying distinct subgroups within refractory AML is crucial for understanding disease progression and therapeutic resistance.

Purpose of the Study:

  • To define and characterize a subgroup of AML patients with highly refractory disease.
  • To investigate the cytogenetic and molecular features associated with this highly refractory AML subgroup.

Main Methods:

  • Evaluation of 103 patients with refractory AML post-induction chemotherapy.
  • Definition of highly refractory AML based on peripheral blast cell persistence ( >1 G/L between days 12-16).
  • Cytogenetic analysis and assessment of multidrug-resistance factors (P-glycoprotein and lung resistance protein) in a subset of patients.

Related Experiment Videos

Main Results:

  • Seven patients (6.8% of refractory AML) met criteria for highly refractory AML.
  • High co-expression of P-glycoprotein (P-gp) and lung resistance protein (LRP) was observed in all tested highly refractory patients.
  • Four of six highly refractory patients exhibited complex cytogenetic aberrations, while two had normal karyotypes.

Conclusions:

  • Highly refractory AML is characterized by a distinct profile of genetic complexity and multidrug resistance.
  • The co-expression of P-gp and LRP suggests a significant role for drug efflux pumps in treatment failure in this AML subgroup.
  • Further research into targeted therapies addressing these resistance mechanisms is warranted for highly refractory AML patients.